The Reformulation Playbook: How Pharma Uses 505(b)(2) to Lock In New Patents, Block Generics, and Reset Prices
The Mechanism Most Analysts Still Underestimate Every few years, a drug that has been off-patent for a decade reappears in […]
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook
How to turn expiring blockbusters into budget wins — before your competitors do Patent cliffs don’t sneak up on anyone.
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook Read Post »
Patent Expiration Data: The Procurement Playbook That Cuts Your Drug Spend by 80%
How hospital systems, PBMs, and self-insured employers can use IP intelligence to time generic switches and eliminate billions in avoidable
Patent Expiration Data: The Procurement Playbook That Cuts Your Drug Spend by 80% Read Post »
The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Imperil Sponsor Patents
Darshan Kulkarni PharmD, MS, Esq. www.kulkarnilawfirm.com Introduction The intersection of intellectual property (IP) and artificial intelligence (AI) has triggered a
Drug Patents in New Zealand: The Hard 20-Year Limit That Shapes Every Generic Entry Decision
A complete guide for pharmaceutical executives, IP strategists, generic manufacturers, and investors navigating one of the world’s most distinctive patent
Patent Box Tax Strategy: The Definitive Guide to Pharma IP Tax Optimization
The UK Patent Box slashes the effective corporation tax rate on patented-drug profits from 25% to 10%. That 15-percentage-point gap
Patent Box Tax Strategy: The Definitive Guide to Pharma IP Tax Optimization Read Post »
How 180 Days Can Make or Break a Generic Drug Launch: The ANDA Exclusivity Playbook
Generic drug companies do not compete on science. They compete on timing, legal nerve, and an encyclopedic understanding of a
How 180 Days Can Make or Break a Generic Drug Launch: The ANDA Exclusivity Playbook Read Post »
Find Top Biopharma Talent Before Anyone Else: The Patent-to-Pipeline Hiring Playbook
The most sought-after scientists in biopharma rarely post their resumes to LinkedIn. They don’t have to. Their work announces them
Find Top Biopharma Talent Before Anyone Else: The Patent-to-Pipeline Hiring Playbook Read Post »
Europe’s Divisional Patent Trap: How Big Pharma Delays Generics Without Ever Losing in Court
When a European patent dies — formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal
